Cargando…

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease

Esophageal adenocarcinoma (EAC) is a deadly disease with limited therapeutic options. In the present study, we determined the preclinical efficacy of CDK4/6 inhibitor abemaciclib for treatment of EAC. In vitro, apoptosis, proliferation, and pathway regulation were evaluated in OE19, OE33, and FLO1 E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosovec, Juliann E., Zaidi, Ali H., Omstead, Ashten N., Matsui, Daisuke, Biedka, Mark J., Cox, Erin J., Campbell, Patrick T., Biederman, Robert W.W., Kelly, Ronan J., Jobe, Blair A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725031/ https://www.ncbi.nlm.nih.gov/pubmed/29245989 http://dx.doi.org/10.18632/oncotarget.22244

Ejemplares similares

High yield reproducible rat model recapitulating human Barrett’s carcinogenesis
por: Matsui, Daisuke, et al.
Publicado: (2017)

Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma
por: Babar, Laila, et al.
Publicado: (2019)

Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model
por: Zaidi, Ali H., et al.
Publicado: (2021)

Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma
por: Matsui, Daisuke, et al.
Publicado: (2016)

The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy
por: Kosovec, Juliann E., et al.
Publicado: (2018)

Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
por: Matani, Hirsch, et al.
Publicado: (2022)

Magnetic sphincter augmentation (MSA) in patients with hiatal hernia: clinical outcome and patterns of recurrence
por: Ayazi, Shahin, et al.
Publicado: (2019)

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Magnetic Sphincter Augmentation and Postoperative Dysphagia: Characterization, Clinical Risk Factors, and Management
por: Ayazi, Shahin, et al.
Publicado: (2019)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Establishing Magnetic Resonance Imaging as an Accurate and Reliable Tool to Diagnose and Monitor Esophageal Cancer in a Rat Model
por: Kosovec, Juliann E., et al.
Publicado: (2014)

Measurement of outflow resistance imposed by magnetic sphincter augmentation: defining normal values and clinical implication
por: Ayazi, Shahin, et al.
Publicado: (2020)

Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
por: Liang, Muh-Lii, et al.
Publicado: (2020)

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
por: Gharbi, Severine Isabelle, et al.
Publicado: (2022)

An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum
por: Habler, Katharina, et al.
Publicado: (2022)

Organisation: Voluntary, or Compelled?
Publicado: (1918)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
por: Sun, Chao-Yue, et al.
Publicado: (2022)

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
por: Gharbi, Severine Isabelle, et al.
Publicado: (2022)

Abemaciclib for breast cancer
Publicado: (2020)

Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas
por: Tanaka, Yuka, et al.
Publicado: (2020)

Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma
por: Zaidi, Ali H., et al.
Publicado: (2016)

Cardiovascular Magnetic Resonance Imaging—Incremental Value in a Series of 361 Patients Demonstrating Cost Savings and Clinical Benefits: An Outcome-Based Study
por: Hegde, Vinayak A, et al.
Publicado: (2017)

Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1
por: Tayshetye, Pritam, et al.
Publicado: (2022)

Contributing Chemistry and Compelling Physics
Publicado: (2013)

Is the Act of Compelling Vaccination Unconstitutionial?
por: Wyatt, Thomas M.
Publicado: (1892)

Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro
por: Guney Eskiler, Gamze, et al.
Publicado: (2021)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget’s Disease
por: Takahashi, Gary W, et al.
Publicado: (2022)

Fifteen compelling open questions in plant cell biology
por: Roeder, Adrienne H K, et al.
Publicado: (2021)

Livedoid vasculopathy: a compelling diagnosis
por: Freitas, Thiago Quadrante, et al.
Publicado: (2018)

Mitophagy and Neuroinflammation: A Compelling Interplay
por: Charmpilas, Nikolaos, et al.
Publicado: (2023)

Disadvantaged children: what have they compelled us to learn?
por: Richmond, J. B.
Publicado: (1970)

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
por: Bouclier, Celine, et al.
Publicado: (2020)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

Prognostic Value and Targeted Inhibition of Survivin Expression in Esophageal Adenocarcinoma and Cancer-Adjacent Squamous Epithelium
por: Malhotra, Usha, et al.
Publicado: (2013)

A compelling need to empirically validate bipolar depression
por: Martino, Diego J., et al.
Publicado: (2023)

MicroRNA Signature Characterizes Primary Tumors That Metastasize in an Esophageal Adenocarcinoma Rat Model
por: Zaidi, Ali H., et al.
Publicado: (2015)

Ten simple rules for writing compelling recommendation letters
por: Kong, Jennifer H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h9l68cfq8kkm0s3k0cgcqvmj55